6,7,4'-Trihydroxyflavanone

Research use only, not for human use.

6,7,4'-Trihydroxyflavanone possesses various pharmacological activities, including anti-rheumatic, anti-ischemic, anti-inflammatory, anti-osteoclastogenic, and protective effects against METH-induced deactivation of T cells. 6,7,4'-Trihydroxyflavanone can be used for studies about the treatment of METH-addicts suffering from neurodegenerative diseases.

6,7,4'-Trihydroxyflavanone possesses various pharmacological activities, including anti-rheumatic, anti-ischemic, anti-inflammatory, anti-osteoclastogenic, and protective effects against METH-induced deactivation of T cells. 6,7,4'-Trihydroxyflavanone can be used for studies about the treatment of METH-addicts suffering from neurodegenerative diseases.(In Vitro):6,7,4'-Trihydroxyflavanone (40 μM) did not lead to cytotoxicity, but attenuated METH-induced neurotoxicity by modulating the expression of apoptosis-related proteins, METH-induced oxidative stress, and PI3K/Akt/mTOR phosphorylation in METH-exposed SH-SY5y cells. 6,7,4'-Trihydroxyflavanone induced Nrf2 nuclear translocation and HO-1 expression. The induction of HO-1 by 6,7,4'-Trihydroxyflavanone attenuates METH-induced neurotoxicity.(In Vivo):6,7,4'-Trihydroxyflavanone (20 and 50 mg/kg; orally) alleviates dextran sulfate sodium (DSS)-induced colitis by modulating the activity of T cells and colon cells in vivo including a reduction in body weight, shrinkage of the colon, and enhanced expression of pro-inflammatory cytokines in the colon and mesenteric lymph nodes.

——

——

——

Others

Other Targets

——

——

——

189689-31-4

272.25

C15H12O5

>98% (HPLC)

——

O=C1C2=CC(O)=C(O)C=C2OC(C3=CC=C(O)C=C3)C1

——

(-20℃)

With Ice Pack

≥ 2 years